SCHEMBL15966236

SCHEMBL15966236

CCCCO[C@@H]1OC(COC(=O)c2ccccc2)[C@@H](O[C@@H]2OC(CO)[C@H](O)C(O[C@@H]3OC(CO)CC[C@@H]3C)[C@@H]2OC(=O)c2ccccc2)C(OC(=O)c2ccccc2)[C@@H]1OC(=O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 5/20 0.41
LGALS9 O00182 4/20 0.41
LGALS1 P09382 4/20 0.41
LGALS7; LGALS7B P47929 3/20 0.41
SELE P16581 3/20 0.39
MAOB P27338 1/20 0.37
SELP P16109 5/20 0.37
LGALS4 P56470 1/20 0.35
ANTXR2 P58335 1/20 0.35
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
LGALS8 O00214 2/20 0.34
F11 P03951 1/20 0.34
ELANE P08246 1/20 0.34
PTPN1 P18031 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12454166 0.89 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELE
SCHEMBL14685786 0.89 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELE
SCHEMBL15473995 0.89 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELE
SCHEMBL15966237 0.87 MAOB (0.45) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELE
SCHEMBL15966246 0.84 MAOB (0.42) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELE
SCHEMBL15966260 0.82 ANTXR2 (0.42) LGALS3LGALS9LGALS1LGALS7; LGALS7BMAOB
SCHEMBL19277202 0.81 LGALS3 (0.44) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELE
SCHEMBL16258134 0.80 PTPN1 (0.42) LGALS3LGALS9LGALS1LGALS7; LGALS7BANTXR2
SCHEMBL15966245 0.80 PRKCA (0.38) LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP
SCHEMBL16360943 0.80 LGALS3 (0.51) LGALS3LGALS9LGALS1LGALS7; LGALS7BMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140235850-A1 SYNTHESIS OF HMO CORE STRUCTURES GLYCOM A/S (DK) 2014-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235850-A1 SYNTHESIS OF HMO CORE STRUCTURES GNE, OGT, GALE LGALS3 165/4885LGALS9 233/4885LGALS1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.